HUE025545T2 - Izoxazolo-piridin-származék - Google Patents

Izoxazolo-piridin-származék Download PDF

Info

Publication number
HUE025545T2
HUE025545T2 HUE14168581A HUE14168581A HUE025545T2 HU E025545 T2 HUE025545 T2 HU E025545T2 HU E14168581 A HUE14168581 A HU E14168581A HU E14168581 A HUE14168581 A HU E14168581A HU E025545 T2 HUE025545 T2 HU E025545T2
Authority
HU
Hungary
Prior art keywords
methyl
isoxazol
ylmethoxy
phenyl
mmol
Prior art date
Application number
HUE14168581A
Other languages
English (en)
Inventor
Bernd Buettelmann
Henner Knust
Roetne Roland Jakob
Matthew C Lucas
Andrew Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HUE025545T2 publication Critical patent/HUE025545T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (6)

  1. M EP 2 Τ6Τ 536 iajstromszámű európai szabadalom ígényporítjainak magyar fordítása; lzo;xazo!0“$ari(lió-származék Szabacfaimi igénypontok: 1,1 :képlety vegyufet
    ϊ vagy gyógyászatifog elfogadható sója, adgl X jelentése *0- vagy -NH- csoport; RS: jelentése: fenti“, plrldlnltt vagy pirtmídíoiieseporL ámenek mindegyike adott esetben helyettesített 1,2 vagy 3 hategénafommal ijR2Íebrtfése H atom vagy -0¾ vagy -CFy csoport; R3 és Bejelentése H atom, halogénafom, ~CN vagy Cí^aikil-osópört; R4 jelentése ~C(0}~NRhRo csoport, ahol Rb és Rc agyüt a nfegénatommai amelyhez kapcsolódnak, rtetemclkyhraólekularészf alkot,: amely adót esetben helyettesített egy vagy több A csoporttal; ÎT jelentőse B atom:, ~€F3j benzUoxh adói esetben egy metiíösoporttaí helyettesített i^tmliidiríöpírídtintlsssopopt,. -Q<O)^iRfeF^f:-<5S0p0:rt:! ahol Rb és R4, jelentése egymástól függetlenül H atom vagy rnoríoltnílcsoport; Aielentlsi hldrokpi oxo-, C^aiklfo Cfoafkoxl·, Gí..?halögénafkíR Ci./hldroxialkil-csoport, halogénatom vagy ~CtR csoport; ahol a “ hete roeí k 11 l-roo íeku la rész" fogalom egy vegyértékű telített vagy részlegesen telített 3-?4agü monociklusos vagy 9-1 (Magú hícikíusos gyűrűrendszerre utal., ahol egy, két, három vagy négy győrö^szenatomol; Ns 0 vagy S helyettesít, és a kapcsolódási pont az említett gylrűrendszer telített: vagy részlegesen telítetlen gyűrűjén van.
  2. 2. Az 1, igénypont slants vegyület, atíöl R2 jelentése metik vagy thbuormetilesopori
  3. 3., Az l yagy I, ií^jénypont ibÉfTT*^M^0' vegyület, ahol ff jelentése Hl atom, ~ GM vagy metílcsoport 111-3. igénypontok bármelyike szánni vegyület, ahol; ff jelentése H, Erstem vagy metilcsoport S. Az 1-4. igénypontok bármelyike szerinti vegyülni ahol ff~ben a hneterocikfi!-molskütarészt a morfolniH tiomorfolníio 5!67\8-l:ötraliidrö41.2,4|tnazolO''[4;3-a|girazini- és a 4,5,6,7~tetr3hid ro-pirazolq|1 ,δ-ajpinmldinil-esopofî közül választjuk, amelyek mindegyike adott esetben helyettesített egy vagy több A csoporttal. 0» Az 1 -5 Igénypontok bármelyiké szerinti vegyület, ahol ffjelentese H atom; vagy-CF* csoport,
  4. 7, Az 1 -8, Igénypontok bánnelyike szehoth vegyület, ahol R:> jelentése H atom vagy ~ CF;< csoport, ff és ff jelentése ti atom, halogénatom, -CN vagy C$..?alkikcsopörí.
  5. 8, Az 1-7. Igénypontok bármelyike szerinti vegyület, ahol a vegyület (1,1 ~dloxo~1 λ6-tiomorfoSin-4-il)-|{>-(3a'4-fluorrtenil}-5-metil~izoxazoG4-ilm:etoxi]-psridrs-3-il}'-metanon. a. A 8. igénypont szerinti vegyület, amely megkapható 64344'-fluor-feníi}-5-metll-· lzo>mzol-4-|metoxi]-nikotinsav és iomorfeln-S:!iS"dtexld reakciójával, 10, A $3, igénypont szerinti vegyület, aboi 2-Ç1ffhenzoîriazol-1^41)-11,3,3-tetramelluiröníymrtetrafiuorborátol és tiomorfolln-S.SffioxIdot adunk 6-[3-(4-fSuor-· íen$|4^moiilNi^^ DMF-ben készült oldatához. 11„ Az 1-10. igénypontok bármelyike szerinti vegyület gyógyszerként való alkalmazásra:,
  6. 12. Gyógyszer, amely tartalmaz legalább égf azi-iO.. igénypontok bármelyike szerinti I képletü vegyületet. 13.. A 12. igénypont szerinti gyógyszer kognitiv rendellenességek Zselésében vagy kognitív fokozóKént való alkalmazásra, 14. Ä 13, Igénypont szerinti gyógyszer Alzheimer-betegség kezelésében való alkalmazásra.
HUE14168581A 2007-12-04 2008-11-26 Izoxazolo-piridin-származék HUE025545T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122240 2007-12-04

Publications (1)

Publication Number Publication Date
HUE025545T2 true HUE025545T2 (hu) 2016-03-29

Family

ID=40329314

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14168581A HUE025545T2 (hu) 2007-12-04 2008-11-26 Izoxazolo-piridin-származék

Country Status (34)

Country Link
US (6) US20090143371A1 (hu)
EP (2) EP2767536B1 (hu)
JP (1) JP5301557B2 (hu)
KR (2) KR101237576B1 (hu)
CN (1) CN101889010B (hu)
AR (1) AR069523A1 (hu)
AU (1) AU2008333326B2 (hu)
BR (1) BRPI0820112B8 (hu)
CA (1) CA2707648C (hu)
CL (1) CL2008003591A1 (hu)
CO (1) CO6351788A2 (hu)
CR (1) CR11454A (hu)
CY (2) CY1116119T1 (hu)
DK (2) DK2227467T3 (hu)
EC (1) ECSP10010230A (hu)
ES (2) ES2550994T3 (hu)
HK (1) HK1149756A1 (hu)
HR (2) HRP20150348T1 (hu)
HU (1) HUE025545T2 (hu)
IL (1) IL205759A (hu)
MA (1) MA31865B1 (hu)
MX (1) MX2010005717A (hu)
MY (1) MY156747A (hu)
NZ (1) NZ585308A (hu)
PE (2) PE20130242A1 (hu)
PL (2) PL2227467T3 (hu)
PT (2) PT2767536E (hu)
RS (2) RS53877B1 (hu)
RU (1) RU2484091C2 (hu)
SI (2) SI2227467T1 (hu)
TW (1) TWI363624B (hu)
UA (1) UA100132C2 (hu)
WO (1) WO2009071476A1 (hu)
ZA (1) ZA201003631B (hu)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0820112B8 (pt) 2007-12-04 2021-05-25 Hoffmann La Roche derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
CA2740366A1 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
EP2942346B1 (en) 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
US8389550B2 (en) * 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) * 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
WO2010127976A1 (en) * 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives
AU2010244551A1 (en) * 2009-05-05 2011-12-01 F. Hoffmann-La Roche Ag Isoxazole-thiazole derivatives as GABA A receptor inverse agonists for use in the treatment of cognitive disorders
CA2760746C (en) * 2009-05-05 2017-07-11 F. Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
BRPI1013766A2 (pt) 2009-05-07 2016-04-05 Hoffmann La Roche "derivados de isoxazol-piridina como moduladores de gaba"
BR112012006330A2 (pt) * 2009-09-21 2017-07-04 Janssen Cilag S A análogos de o-benzil nicotinamida como moduladores alostéricos positivos de mglur5
BR112012018631A8 (pt) 2010-01-28 2017-12-19 President And Fellows Of Harvard Colege composições e métodos para intensificação da atividade do proteassoma
US20130210836A1 (en) 2010-07-19 2013-08-15 Syngenta Crop Protection Llc Microbicides
BR112013001237A2 (pt) 2010-07-19 2016-05-17 Syngenta Participations Ag compostos de isoxazola, isoatiazola, furano e tiofeno como microbicidas
AU2011293612B2 (en) 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
KR20150123967A (ko) * 2010-11-05 2015-11-04 에프. 호프만-라 로슈 아게 중추 신경계 질환의 치료를 위한 활성 약학 화합물의 용도
EP2457569A1 (en) 2010-11-05 2012-05-30 F. Hoffmann-La Roche AG Use of active pharmaceutical compounds for the treatment of central nervous system conditions
EP2707101B1 (en) 2011-05-12 2019-02-13 Proteostasis Therapeutics, Inc. Proteostasis regulators
US8785435B2 (en) * 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US8604062B2 (en) * 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
CN104135859B (zh) 2011-12-28 2017-06-27 全球血液疗法公司 取代的苯甲醛化合物及其用于增加组织氧合的方法
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN104411699B (zh) 2012-06-26 2017-06-13 萨尼奥纳有限责任公司 苯基三唑衍生物及其用于调节gabaa 受体复合体的用途
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008721A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
MY183637A (en) * 2013-03-15 2021-03-04 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PT3102208T (pt) 2014-02-07 2021-04-05 Global Blood Therapeutics Inc Polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3 il)metoxi)benzaldeído
JP2017071553A (ja) * 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
UA125524C2 (uk) * 2016-12-08 2022-04-13 Ф. Хоффманн-Ля Рош Аг Ефірні похідні ізоксазолу як позитивні алостеричні модулятори рецептора гамк а альфа-5
CA3074110A1 (en) * 2017-08-28 2019-03-07 University Of Maryland, Baltimore Novel gamma aminobutyric acid type a receptor modulators for mood disorders
BR112020012518A2 (pt) * 2017-12-22 2020-11-24 Bayer Aktiengesellschaft hidroxi-isoxazolinas e derivados das mesmas
IL279266B2 (en) * 2018-06-13 2024-03-01 Hoffmann La Roche New Isoxazolyl Ether History as GABA A ALPHA5 PAM
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US20240043418A1 (en) 2020-03-26 2024-02-08 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
AU2022270411A1 (en) 2021-05-05 2023-11-23 University College Cardiff Consultants Limited Heteroaryl compounds useful in the treatment of cognitive disorders
CN116854680A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-杂环类衍生物、药物组合物和用途
CN115286636A (zh) * 2022-10-08 2022-11-04 上海赛默罗生物科技有限公司 烟酰胺晶型及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812225A1 (de) * 1988-04-13 1989-10-26 Basf Ag Isoxazol(isothiazol)-5-carbonsaeureamide
EP1102755B1 (en) 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
DE19920791A1 (de) * 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
GB0125086D0 (en) 2001-10-18 2001-12-12 Merck Sharp & Dohme Novel compounds
US20060148858A1 (en) 2002-05-24 2006-07-06 Tsuyoshi Maekawa 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
GB0221443D0 (en) * 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
WO2005113519A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
KR100876784B1 (ko) * 2004-10-01 2009-01-07 에프. 호프만-라 로슈 아게 헥사플루오로아이소프로판올 치환된 에터 유도체
DE602006017694D1 (de) * 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
DE602006003777D1 (de) 2005-09-19 2009-01-02 Hoffmann La Roche Isoxazolderivate als inverse gaba a alpha5 agonisten
EP1937674A1 (en) * 2005-10-11 2008-07-02 F.Hoffmann-La Roche Ag Isoxazole derivatives
EP1968972B1 (en) * 2005-12-23 2012-11-28 F. Hoffmann-La Roche AG Aryl-isoxazolo-4-yl-oxadiazole derivatives
ATE537171T1 (de) 2005-12-27 2011-12-15 Hoffmann La Roche Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
PL1968973T3 (pl) 2005-12-27 2012-03-30 Hoffmann La Roche Pochodne aryloizoksazol-4-iloimidazolu
CA2636112A1 (en) 2006-01-17 2007-07-26 F.Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives useful for the treatment of alzheimer's disease via gaba receptors
BRPI0820112B8 (pt) 2007-12-04 2021-05-25 Hoffmann La Roche derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
EP2229383B1 (en) 2007-12-04 2017-01-18 F. Hoffmann-La Roche AG Isoxazolo-pyrazine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US20100280019A1 (en) * 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles

Also Published As

Publication number Publication date
KR101237576B1 (ko) 2013-03-04
UA100132C2 (en) 2012-11-26
AU2008333326B2 (en) 2013-05-30
PL2227467T3 (pl) 2015-05-29
EP2767536B1 (en) 2015-09-02
AR069523A1 (es) 2010-01-27
RU2010123923A (ru) 2012-01-10
CR11454A (es) 2010-06-28
CL2008003591A1 (es) 2010-01-04
PT2227467E (pt) 2015-03-02
IL205759A0 (en) 2010-11-30
CY1116119T1 (el) 2017-02-08
BRPI0820112A2 (pt) 2015-05-05
ES2531023T3 (es) 2015-03-09
HK1149756A1 (en) 2011-10-14
DK2227467T3 (en) 2015-01-19
KR20100075669A (ko) 2010-07-02
NZ585308A (en) 2012-03-30
PE20130242A1 (es) 2013-03-04
TW200924763A (en) 2009-06-16
US20130274467A1 (en) 2013-10-17
RU2484091C2 (ru) 2013-06-10
ZA201003631B (en) 2013-10-30
US8877782B2 (en) 2014-11-04
PT2767536E (pt) 2015-11-17
PL2767536T3 (pl) 2016-01-29
US20130274469A1 (en) 2013-10-17
US20090143371A1 (en) 2009-06-04
CY1116902T1 (el) 2017-04-05
EP2767536A1 (en) 2014-08-20
CO6351788A2 (es) 2011-12-20
RS53877B1 (en) 2015-08-31
MA31865B1 (fr) 2010-11-01
US8518974B2 (en) 2013-08-27
DK2767536T3 (en) 2015-10-19
US8877783B2 (en) 2014-11-04
PE20091073A1 (es) 2009-07-23
KR20120102117A (ko) 2012-09-17
AU2008333326A1 (en) 2009-06-11
EP2227467B1 (en) 2014-12-31
RS54355B1 (en) 2016-04-28
CA2707648A1 (en) 2009-06-11
US20130274468A1 (en) 2013-10-17
US20120184538A1 (en) 2012-07-19
SI2227467T1 (sl) 2015-03-31
IL205759A (en) 2014-07-31
CN101889010B (zh) 2012-12-05
HRP20150348T1 (hr) 2015-05-08
EP2227467A1 (en) 2010-09-15
JP2011505401A (ja) 2011-02-24
SI2767536T1 (sl) 2015-12-31
WO2009071476A1 (en) 2009-06-11
ES2550994T3 (es) 2015-11-13
CA2707648C (en) 2014-08-12
JP5301557B2 (ja) 2013-09-25
US9073908B2 (en) 2015-07-07
BRPI0820112B8 (pt) 2021-05-25
MX2010005717A (es) 2010-06-02
US8846719B2 (en) 2014-09-30
TWI363624B (en) 2012-05-11
ECSP10010230A (es) 2010-07-30
US20130281690A1 (en) 2013-10-24
BRPI0820112B1 (pt) 2019-01-15
MY156747A (en) 2016-03-31
HRP20151250T1 (hr) 2015-12-18
CN101889010A (zh) 2010-11-17

Similar Documents

Publication Publication Date Title
HUE025545T2 (hu) Izoxazolo-piridin-származék
EP2414354B1 (en) Hydroxy-methyl isoxazole derivatives as gaba a modulators
EP2427456B1 (en) Isoxazole-pyridine derivatives
CA2706990A1 (en) Isoxazolo-pyrazine derivatives
KR20120013408A (ko) 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
KR20100031586A (ko) 피리미도디아제피논 유도체
AU2013203735A1 (en) Isoxazolo-pyridine derivatives